Want to see ADIL full AI Analyst Report?
Top Page
Adial Pharmaceuticals
(NASDAQ:ADIL)
Select Model
Select Model
Rating:46Neutral
Price Target:
$5.50
▲(97.84% Upside)
Action:Reiterated
Date:08/22/26
The score is primarily constrained by weak financial performance (pre-revenue, sharply wider TTM losses, continued cash burn, and negative equity). Technicals are supportive in trend terms (price above major moving averages with positive MACD) but are tempered by overbought signals (high RSI/Stoch). Valuation provides limited support due to negative earnings and no dividend, while corporate events add downside risk from Nasdaq listing compliance challenges despite a strategically positive merger/financing.
Positive Factors
Minimal Debt
Essentially no debt reduces refinancing and interest-rate exposure, preserving flexibility while the company funds clinical development. This is a relative strength, although it does not offset the substantial equity deficit and ongoing need for capital.
Negative Factors
Pre-Revenue and Widening Losses
ADIL remains dependent on clinical and regulatory success because it has no reported commercial revenue. The sharp increase in losses indicates heavier spending without corresponding revenue generation, raising execution risk and prolonging the path to self-sufficiency.
Read all positive and negative factors
Positive Factors
Negative Factors
Minimal Debt
Essentially no debt reduces refinancing and interest-rate exposure, preserving flexibility while the company funds clinical development. This is a relative strength, although it does not offset the substantial equity deficit and ongoing need for capital.
Read all positive factors
Adial Pharmaceuticals (ADIL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$15.28M
Dividend YieldN/A
Average Volume (3M)102.19K
Price to Earnings (P/E)―
Beta (1Y)1.32
Revenue GrowthN/A
EPS Growth45.78%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-16.53
Shares Outstanding2,625,890
10 Day Avg. Volume29,103
30 Day Avg. Volume102,186
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.32
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.50Price Target Upside205.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Adial Pharmaceuticals Business Overview & Revenue Model
Company Description
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its prim...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Adial has historically not generated meaningful recurring revenue from commercial product sales because its primary drug candidate(s) have been in development rather than approved and marketed. Its ab...
Adial Pharmaceuticals Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -141.00 | 0.00 | 0.00 | -564.00 | 0.00 | 0.00 |
| EBITDA | -57.80M | -7.98M | -13.20M | -7.00M | -10.80M | -17.69M |
| Net Income | -57.80M | -7.98M | -13.20M | -7.00M | -12.73M | -19.42M |
Balance Sheet | ||||||
| Total Assets | 29.09M | 6.80M | 5.04M | 4.74M | 5.73M | 7.63M |
| Cash, Cash Equivalents and Short-Term Investments | 28.71M | 5.88M | 3.75M | 2.83M | 4.00M | 6.06M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 207.38K | 256.96K |
| Total Liabilities | 28.93M | 1.52M | 975.86K | 653.51K | 2.46M | 4.13M |
| Stockholders Equity | 156.00K | 5.28M | 4.07M | 4.08M | 3.28M | 3.51M |
Cash Flow | ||||||
| Free Cash Flow | -11.13M | -6.49M | -6.92M | 0.00 | -11.19M | -12.01M |
| Operating Cash Flow | -11.13M | -6.49M | -6.92M | -6.81M | -11.19M | -11.95M |
| Investing Cash Flow | 5.28M | 150.00K | 0.00 | 1.50M | 0.00 | -34.02K |
| Financing Cash Flow | 28.65M | 8.47M | 7.85M | 4.13M | 9.13M | 13.64M |
Adial Pharmaceuticals Technical Analysis
Positive
2.78
Price Trends
3.45
Positive
2.65
Positive
3.79
Positive
Market Momentum
0.73
Negative
67.42
Neutral
76.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADIL, the sentiment is Positive. The current price of 2.78 is below the 20-day moving average (MA) of 4.54, below the 50-day MA of 3.45, and below the 200-day MA of 3.79, indicating a bullish trend. The MACD of 0.73 indicates Negative momentum. The RSI at 67.42 is Neutral, neither overbought nor oversold. The STOCH value of 76.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ADIL.
Adial Pharmaceuticals Risk Analysis
Adial Pharmaceuticals disclosed 80 risk factors in its most recent earnings report. Adial Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Adial Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $3.39M | -0.02 | -438.03% | ― | ― | 53.95% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $11.46M | -1.03 | -59.30% | ― | ― | 19.38% | |
46 Neutral | $15.28M | -0.36 | -162.83% | ― | ― | 45.78% | |
43 Neutral | $4.48M | -0.27 | -64.10% | ― | ― | 71.38% | |
42 Neutral | $2.90M | -0.16 | -204.27% | ― | ― | 68.91% |
* Healthcare Sector Average
ADIL
Adial Pharmaceuticals
5.94
-3.62
-37.88%
GLMD
Galmed Pharmaceuticals
4.33
-6.79
-61.06%
KPRX
Kiora Pharmaceuticals
2.59
-0.27
-9.44%
MTNB
Matinas BioPharma
0.20
-1.78
-90.10%
ALZN
Alzamend Neuro
1.67
-0.79
-32.11%
CLDI
Calidi Biotherapeutics
1.35
-25.37
-94.95%
Adial Pharmaceuticals Corporate Events
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder Meetings
Adial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge
Negative
Aug 21, 2026
On August 18, 2026, Adial Pharmaceuticals received a notice from Nasdaq that it no longer meets the $2.5 million minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, and also fails to qualify under alt...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Adial Pharmaceuticals Plans Major Leadership and Board Transition
Negative
Aug 13, 2026
As of August 10, 2026, Adial Pharmaceuticals announced that, contingent on stockholder approval of certain proposals at its 2026 annual meeting, President and CEO Cary Claiborne and CFO Vinay Shah are expected to be terminated and receive contract...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and Financing
Adial Pharmaceuticals Completes Azora Merger, Shifts Strategic Focus
Positive
Jun 11, 2026
On June 11, 2026, Adial Pharmaceuticals completed the acquisition of Azora Therapeutics, exchanging Azora’s equity for 437,474 Adial common shares and about 12,930 Series A non-voting convertible preferred shares, and secured up to $64 milli...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.